Navigation Links
SENOMYX ANNOUNCES FOURTH QUARTER AND YEAR-END 2008 FINANCIAL RESULTS
Date:2/12/2009

oling flavors that do not have the limitations of currently available agents. Senomyx has initiated taste tests of samples that were active in the Company's proprietary high-throughput screening assay designed to identify potential new cooling agents. In a recent advance, preliminary results indicated that a newly identified sample provided a cooling taste effect. This and other samples will be investigated further.

Management Update:

Mark Zoller, Ph.D., Senomyx's Chief Scientific Officer and Executive Vice President of Discovery and Development, will be taking a medical leave and is expected to return in June. Although Dr. Zoller will not be on site, Senomyx anticipates that he will continue to provide significant input into scientific projects, collaborations, the Scientific Advisory Board, and major decisions relating to the general function and management of the Company. During his leave, day-to-day Discovery and Development responsibilities will be assumed by Donald S. Karanewsky, Ph.D., Senior Vice President, Discovery. Dr. Karanewsky, who joined Senomyx in June 2007, has had a distinguished career that includes leading successful discovery efforts at both large pharmaceutical companies and biotechnology research organizations. He is an inventor on more than 70 U.S. patents and has authored over 50 scientific publications. Dr. Karanewsky received a Ph.D. in Chemistry from Harvard University and a B.S. in Chemistry, Magna Cum Laude, from Stevens Institute of Technology in New Jersey.

"We are grateful for Mark's ongoing contributions and we look forward to his return to full activities," Snyder said. "Senomyx is extremely fortunate to have someone of Don's competence to direct our daily scientific efforts. Under Don's leadership we have had significant advances in the Discovery department, including the identification of S6973, our sucrose enhancer in development
'/>"/>

SOURCE Senomyx, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. SENOMYX ANNOUNCES INITIATION OF DEVELOPMENT ACTIVITIES FOR NEW BITTER BLOCKERS
2. SENOMYX, INC. fourth quarter AND FISCAL YEAR-END 2008 Earnings conference call scheduled for February 12, 2009
3. SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE 11TH ANNUAL NEEDHAM GROWTH STOCK CONFERENCE
4. SENOMYX AND FIRMENICH TO COLLABORATE ON COMMERCIALIZATION OF S2383, A NOVEL ENHANCER OF THE HIGH-INTENSITY SWEETENER SUCRALOSE
5. SENOMYX ANNOUNCES THIRD QUARTER 2008 FINANCIAL RESULTS
6. SENOMYX ANNOUNCES RECEIPT OF MILESTONE PAYMENT FROM THE COCA-COLA COMPANY
7. SENOMYX, INC. THIRD QUARTER 2008 EARNINGS CONFERENCE CALL SCHEDULED FOR NOVEMBER 6, 2008
8. SENOMYX CO-FOUNDER AND SCIENTIFIC ADVISORY BOARD MEMBER ROGER TSIEN, PH.D., AWARDED NOBEL PRIZE IN CHEMISTRY
9. SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE WACHOVIA CONSUMER GROWTH CONFERENCE
10. SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE CANACCORD ADAMS 28TH ANNUAL GLOBAL GROWTH CONFERENCE
11. SENOMYX ANNOUNCES INITIATION OF DEVELOPMENT ACTIVITIES FOR NEW SUCROSE ENHANCER
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... Angeles, California (PRWEB) October 23, 2014 ... ), a specialty pharmaceutical company devoted to bringing ... out-licensing partnerships in 2015. , ViaDerma has developed ... which allows for rapid mass transfer of pharmaceutical ... the body to provide immediate localized therapy. The ...
(Date:10/25/2014)... 24, 2014 This research report ... Starch Based Plastics, Regenerated Cellulose, PCL), by Application ... and Forecasts to 2019”, defines and segments the ... forecast of its global volume and value. , ... spread through 178 Slides and in-depth TOC on ...
(Date:10/25/2014)... Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) ... the development of oral drug delivery systems, announced today ... present at FireRock Capital,s Micro-Cap Conference. ... Tuesday, October 28, 2014 ,Time: 9:15am EST ,Location: The ... , About The FireRock Conference  ...
(Date:10/25/2014)... October 24, 2014 ... ) has announced the addition of the  ... And Other 2-D Nanomaterials "  report to ... , ,CNTs and graphene are the strongest, ... man, with a performance-per-weight greater than any ...
Breaking Biology Technology:ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015 2ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015 3Biodegradable Plastics Market Projected to $3,476.87 Million by 2019 - Report by MarketsandMarkets 2Biodegradable Plastics Market Projected to $3,476.87 Million by 2019 - Report by MarketsandMarkets 3Biodegradable Plastics Market Projected to $3,476.87 Million by 2019 - Report by MarketsandMarkets 4Oramed to Present at the FireRock Annual Micro-Cap Conference 2Oramed to Present at the FireRock Annual Micro-Cap Conference 3The Global Market for Carbon Nanotubes, Graphene and Other 2-D Nanomaterials 2The Global Market for Carbon Nanotubes, Graphene and Other 2-D Nanomaterials 3The Global Market for Carbon Nanotubes, Graphene and Other 2-D Nanomaterials 4
... SAN DIEGO, March 29, 2011 Marshall Edwards, Inc.(Nasdaq: ... the clinical development of novel therapeutics targeting cancer metabolism, ... inhibitor program has been accepted for a late-breaking poster ... Annual Meeting on Monday, April 4, 2011 at 1:00 ...
... EXTON, Pa., March 29, 2011 Morphotek®, Inc., ... it has entered into a collaboration and license ... the parties will collaborate to develop and commercialize ... monoclonal antibody to specifically detect human folate receptor ...
... DIEGO, March 29, 2011 Orexigen® Therapeutics, Inc. (Nasdaq: ... the treatment of obesity, today announced the schedule of ... taking place at the American College of Cardiology (ACC) ... ACC:  Ernest N. Morial Convention Center (Expo Hall), New ...
Cached Biology Technology:Marshall Edwards to Report new Data on Mitochondrial Inhibitor Program at American Association for Cancer Research Annual Meeting 2Marshall Edwards to Report new Data on Mitochondrial Inhibitor Program at American Association for Cancer Research Annual Meeting 3Morphotek®, Inc. Announces an Agreement with Biocare Medical, LLC to Develop and Commercialize A Diagnostic Kit for Detection of Folate Receptor Alpha in Malignant Tissues 2Morphotek®, Inc. Announces an Agreement with Biocare Medical, LLC to Develop and Commercialize A Diagnostic Kit for Detection of Folate Receptor Alpha in Malignant Tissues 3
(Date:10/17/2014)... news release is available in German . ... only a very few drugs. When treating overdoses, doctors are ... is especially difficult if there is a combination of drugs ... playing and accidentally swallows his grandmother,s pills? ETH professor Jean-Christophe ... wanted to find an answer to this question. "The task ...
(Date:10/16/2014)... William and Mary,s Virginia Institute of Marine Science ... Environmental Protection Agency to identify the streams and ... develop tools to help local governments and citizens ... critically on a dataset of tidal-marsh observations first ... with this historical baseline can today,s researchers accurately ...
(Date:10/16/2014)... Melbourne researchers have challenged conventional thinking on how the ... new mechanism for how bowel cancer starts. , The ... maintaining and regenerating the ,crypts, that are a feature ... are involved in bowel cancer development, a controversial finding ... existence. , Using 3D imaging technologies, Dr Chin Wee ...
Breaking Biology News(10 mins):Emergency aid for overdoses 2Emergency aid for overdoses 3EPA grant will help localities conserve headwater wetlands 2EPA grant will help localities conserve headwater wetlands 3Cryptic clues drive new theory of bowel cancer development 2
... Gene scanning techniques developed by Professor Ian Day and ... have a major impact on healthcare in the future. ... by Professor Day and his team in the Human ... been successfully applied to search for rare genetic mutations ...
... volume says Dutch researcher Bas Tomassen. He investigated the uptake ... and human cells. , Cell volume is the outcome ... the cell plasma membrane. A cell can regulate its volume ... Exactly how this process works is still not known. Bas ...
... Scientists at the Albert Einstein College of Medicine have ... causes tuberculosis may soon be able to resist the ... why several disease-causing microbes, including Shigella and E. coli, ... research effort was led by Dr. John S. Blanchard, ...
Cached Biology News:New gene scanning technology marks a major advance in disease research 2Water management in cells 2Einstein researchers identify new way that bacteria develop resistance to antibiotics 2
... 5'GCCNNNN NGGC3' 3'CGGN NNNNCCG5' Inactivation Conditions: Heat ... phenol treatment followed by ethanol precipitation. Storage ... 0.1mM EDTA, 1.0mM DTT, 0.01% BSA, 50% ... ice. Store at -20C. Unit Definition: One ...
...
RABBIT ANTI HUMAN ALPHA-2-ANTIPLASMIN...
... Plus DNA Polymerase with a proprietary thermostable ... fidelity than standard Taq DNA polymerase, Double ... Amplifies DNA templates >20kb, Concentration: 5U/ul, Applications: ... cloning and mutagenesis We are part of ...
Biology Products: